Drug Profile
Influenza virus split vaccine - Chongqing Zhifei Biological Products
Alternative Names: Quadrivalent influenza virus split vaccine - Chongqing Zhifei Biological ProductsLatest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Chongqing Zhifei Biological Products
- Developer Anhui Zhifei Longcom Biopharmaceutical
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 14 Dec 2023 Anhui Zhifei Longcom Biopharmaceutical completes a phase-III clinical trials in Influenza virus infections (Prevention, In infants, In children) in China (IM) (NCT05642078)
- 18 Feb 2023 Phase-III clinical trials in Influenza virus infections (Prevention, In infants, In children) in China (IM) (NCT05642078)
- 14 Dec 2022 Preclinical development is still ongoing for Influenza virus infections (Prevention) in China (Chongqing Zhifei Biological Products pipeline, December 2022)